Physician profile
Mara Lee Beebe
NPI 1033782099
$11,217.50
in general payments reported to CMS, 2019-2025
63 companies · $3,937 in 2025
The $3,937 reported for 2025 was more than what 98% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $342 · 2022: $2,228 · 2023: $1,920 · 2024: $2,790 · 2025: $3,937.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,407 · Education: $240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,406.92 |
| Education | $240.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,828.34 | 2023-2025 | |
| Genzyme Corporation | $703.97 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $651.10 | 2022-2023 | Lynparza, Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $631.15 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $552.75 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $527.91 | 2023-2025 | Xifaxan, Trulance |
| Ardelyx, INC. | $521.56 | 2024-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $437.36 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $389.27 | 2021-2025 | Tremfya, Darzalex, Imbruvica |
| Madrigal Pharmaceuticals | $362.70 | 2024-2025 | Rezdiffra, Resmetirom |
| Seagen INC. | $339.33 | 2021-2023 | Tukysa |
| G1 Therapeutics, INC. | $231.55 | 2022-2023 | Cosela |
| Lilly USA, LLC | $217.96 | 2021-2025 | Omvoh, Verzenio |
| Eisai INC. | $211.70 | 2022-2023 | |
| Ipsen Biopharmaceuticals, INC | $197.11 | 2022-2025 | Iqirvo, Onivyde, Somatuline Depot |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mara Lee Beebe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.